GET DAILY SIGNALSPhibro Animal Health (PAHC) Posts +6.3% Sales Growth in Q1 Fiscal 2027
Key Takeaways
- Phibro Animal Health reported first-quarter fiscal 2027 net sales of $386.8 million, up 6.3% year over year and ahead of consensus estimates.
- Adjusted diluted EPS came in at $0.79, up from $0.73 a year earlier and essentially in line with analyst expectations.
- Adjusted EBITDA rose 4% to $64.3 million.
- Management maintained its full-year fiscal 2027 guidance across net sales, net income, and adjusted earnings.
- Growth was led by the Mineral Nutrition and Performance Products segments, while the core Animal Health business tracked in line with the company's plan.
- For more context, readers can review this ticker's Major News, Today's Price Move, Price Targets, and Forecast pages.
- Explore Trending AI Robots to discover AI-driven trading strategies and market insights.
Why These Results Matter
Phibro Animal Health Corporation (PAHC) develops, manufactures, and markets animal health and mineral nutrition products across three segments: Animal Health, Mineral Nutrition, and Performance Products. Its fiscal year ends June 30, so the quarter ended September 30, 2026 marks the first quarter of fiscal 2027. This report serves as the initial checkpoint against full-year guidance and provides an early signal on demand for vaccines, nutritional specialty products, and mineral nutrition. The company has now beaten consensus EPS estimates for eight straight quarters, which sets a higher standard for execution. I am also watching margin trends closely, since higher SG&A costs and input expenses have weighed on profitability even as revenue expanded.
The Quarter in Detail
For the first quarter of fiscal 2027, PAHC reported net sales of $386.8 million, a 6.3% increase from $363.9 million in the prior-year period. The result topped consensus revenue estimates of roughly $375.4 million. Adjusted diluted EPS reached $0.79, up $0.06 from $0.73 a year ago and nearly matching the consensus estimate of $0.78. GAAP net income rose to $29.5 million from $26.5 million in the prior-year quarter.
Adjusted EBITDA increased 4% to $64.3 million, helped by higher gross profit from sales growth, lower interest expense, and a reduced adjusted effective tax rate. Mineral Nutrition and Performance Products accounted for the outperformance, while the Animal Health segment posted sales in line with plan and Adjusted EBITDA ahead of plan. Adjusted operating margin came in at 12.8%, down from 14.1% a year earlier due to higher SG&A costs. Management kept its fiscal 2027 guidance unchanged, targeting net sales of $1.55 billion to $1.60 billion, net income of $122 million to $132 million, adjusted EBITDA of $258 million to $268 million, and adjusted diluted EPS of $3.41 to $3.59.
How the Market Is Responding
Heading into the release, sentiment leaned cautiously optimistic given PAHC's streak of beating EPS estimates. The sales beat and in-line earnings reinforced that pattern, yet the absence of a guidance raise may temper enthusiasm among growth-focused investors. One area drawing attention is the year-over-year drop in adjusted operating margin, driven by higher SG&A expenses including employee-related costs. This reflects the ongoing challenge of turning solid top-line growth into stronger profitability gains. Segment dynamics also stand out, with a strong start in Mineral Nutrition and Performance Products contrasting a steadier performance in the core Animal Health business. Currency movements and tariff-recovery items played smaller but noticeable roles in the comparisons.
What to Watch Going Forward
Looking ahead, the focus will be on whether PAHC can maintain momentum through the rest of fiscal 2027 while managing costs effectively. The unchanged guidance suggests management expects the positive start to continue, though the margin trajectory remains a key test. The Animal Health segment, which makes up the largest portion of revenue, deserves close attention, particularly vaccine demand in Latin America and international markets along with dairy demand in North America. Mineral Nutrition, where zinc and trace mineral demand supported results, and Performance Products, where copper-based items helped offset softer personal-care ingredient sales, are also worth tracking. Cost pressures from SG&A tied to employee expenses and the Phibro Forward initiatives could continue to affect operating margins, as could input costs, distribution expenses, and foreign currency fluctuations. The guidance assumes no additional foreign exchange gains or losses, so currency shifts could create variability. Balance-sheet metrics such as the 2.9x gross leverage ratio and total debt of $739.6 million will stay relevant as the company balances growth investments with financial flexibility.
My Take on AI-Powered Research Tools
When analyzing names like PAHC, I often turn to Tickeron’s AI tools to cross-check patterns and compare performance across the sector. Their AI Screener, for instance, lets me quickly filter for technical signals, fundamentals, and volatility metrics that complement traditional earnings reviews. I find it helps surface comparable ideas and monitor market shifts without spending hours on manual scans.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
PAHC in -3.16% downward trend, sliding for three consecutive days on November 03, 2026
Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where PAHC declined for three days, in 210 of 285 cases, the price declined further within the following month. The odds of a continued downward trend are 74%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Moving Average Convergence Divergence Histogram (MACD) for PAHC turned negative on October 28, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 45 similar instances when the indicator turned negative. In 32 of the 45 cases the stock turned lower in the days that followed. This puts the odds of success at 71%.
PAHC broke above its upper Bollinger Band on October 02, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 41 of 58 cases where PAHC's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 71%.
The Momentum Indicator moved above the 0 level on November 04, 2026. You may want to consider a long position or call options on PAHC as a result. In 58 of 84 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 69%.
PAHC moved above its 50-day moving average on September 30, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for PAHC crossed bullishly above the 50-day moving average on October 07, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 10 of 15 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 67%.
Following a +2.64% 3-day Advance, the price is estimated to grow further. Considering data from situations where PAHC advanced for three days, in 215 of 286 cases, the price rose further within the following month. The odds of a continued upward trend are 75%.
The Aroon Indicator entered an Uptrend today. In 180 of 247 cases where PAHC Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 73%.
Fundamental Analysis (Ratings)
The Tickeron SMR rating for this company is 34 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 54 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.153) is normal, around the industry mean (7.659). P/E Ratio (16.028) is within average values for comparable stocks, (0.330). Projected Growth (PEG Ratio) (0.350) is also within normal values, averaging (2.202). Dividend Yield (0.012) settles around the average of (0.062) among similar stocks. P/S Ratio (0.953) is also within normal values, averaging (181.047).
The Tickeron Price Growth Rating for this company is 57 (best 1 - 100 worst), indicating steady price growth. PAHC’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 60 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 84, placing this stock slightly better than average.
The Tickeron PE Growth Rating for this company is 92 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a manufacturer of animal health pharmaceutical and nutritional products
Industry PharmaceuticalsGeneric